Type 2 Diabetes

A systematic review and meta-analysis of observational real-world data finds nearly half of patients who begin a GLP-1 RA will discontinue within a year.

A list recapping our most popular endocrinology coverage from the past year.

The FDA's approval marks the second generic approval referencing a GLP-1 receptor agonist in as many months for the agency.

A study finds that individuals with low or high LDL cholesterol levels face a greater cardiovascular risk than those with medium levels.

Real-world data from 18,710 MASH patients highlight the impact of comorbidities, biomarkers, and region on mortality, with 70% of deaths CVD-related.

Observational data point to aldosterone dysregulation as an underrecognized risk factor for hypertension and confirm T2D as a known risk factor.

Patients with hypercortisolism and difficult-to-control type 2 diabetes who received mifepristone exhibited a significant HbA1c improvement in the Phase 4 trial.

Elevated blood insulin levels and insulin resistance each contributed to an elevated risk of colorectal cancer, a new study finds.

A propensity score-matched study from ASH 2024 suggests GLP-1 RA use reduced VTE risk in type 2 diabetes.

A look into how SGLT2 inhibitors, GLP-1 RAs, and nsMRAs have redefined the management of cardio-kidney-metabolic diseases.

Data from SURMOUNT-5, a head-to-head trial, demonstrate tirzepatide offered greater weight loss benefits than semaglutide.

Previous ASA guidance recommended holding GLP-1 RAs in the perioperative period, but new 2024 multisociety guidance suggests a risk-based approach.

Our Endocrinology Month in Review for November 2024 highlights recent headlines in diabetes and endocrinology as well as 5 new episodes of Diabetes Dialogue.

Amgen’s MariTide achieved up to 20% average weight loss at 52 weeks without hitting a plateau in individuals with obesity or overweight.

More than half of US adults—approximately 137 million—are candidates for semaglutide based on diabetes, weight management, or cardiovascular prevention indications.

Reducing systolic blood pressure to less than 120 mmHg lowered the risk of major cardiovascular events for most people with diabetes in the BPROAD trial.

In this first of this 5-part series, Lerma and Lala-Trindade discuss the interplay between chronic kidney disease and cardiovascular disease.

A decade after bariatric surgery, most teens maintained weight loss and reduced obesity-related conditions such as type 2 diabetes and hypertension.

Katherine Tuttle, MD, joins the podcast for a deep dive into the latest FLOW data from Kidney Week 2024.

Richard Pratley, MD, discusses how FLOW mortality data informs the use of semaglutide in patients with chronic kidney disease and type 2 diabetes.

Novo Nordisk will present more detailed data in 2025 and plans to file for an expanded label for Rybelsus for this population.

SGLT2 inhibitors appeared effective in improving hepatic inflammation and fibrosis indices in patients with type 2 diabetes and suspected MASLD.

Brian Hansen, president of CGM at Ascensia Diabetes Care, joins the podcast to discuss the FDA clearance of the Eversense 365 CGM.

Our September 2024 monthly recap in endocrinology spotlights regulatory updates, new guidelines, and the latest episodes of Diabetes Dialogue.

Taher Modarressi, MD, sits down with hosts to share tips and practical nuggets for cardiometabolic health specialists to optimize prescription and adherence to newer therapies.

There were no differences in the treatment effect of ertugliflozin on gout-related outcomes in subgroups based on eric acid quintile or other baseline characteristics.

The FDA has approved the Eversense 365, the world’s first 1-year continuous glucose monitor, with US availability expected in late 2024.

A new study found glucagon-like peptide 1 receptor agonist use was associated with a lower risk of cirrhosis complications for patients with MASLD who did not have cirrhosis.

A follow-up to an earlier episode, this episode features a deep dive into the hosts experience with the Dexcom Stelo sensor.

In this episode, hosts discuss availability of the Abbott Lingo CGM and Embecta’s announcement of FDA clearance for their tubeless patch pump with a 300-unit insulin reservoir.